

Policy Position: Fair and Rational Medicare Payment for Molecular Diagnostic Tests

In support of personalized medicine for the benefit of patients...

Whereas fair and equitable payment for molecular based tests has a direct impact on patient access to this important source of personalized medicine information and whereas undervaluation of such tests has a detrimental effect on access, the PMC supports the following position:

Molecular tests that involve professional services should be placed on the Physician Fee schedule and not on the Clinical Laboratory Fee schedule, in accordance with both the Social Security Act and CMS regulations. The RUC process provides relative values for both the technical and professional components of the test process and is a true reflection of the costs incurred.

Soc Sec Act 42C.F.R. 410.20; 42 U.S.C 1395x(q),(r);
42U.S.C 1395w-4(a)(1) CMS Regulation., Pt 3, Ch5 5114.1

BOARD OF DIRECTORS

President

Edward Abrahams, Ph.D.

Chair

William S. Dalton, Ph.D., M.D.
M2Gen

Vice Chair

Stephen L. Eck, M.D., Ph.D.
Astellas Pharma Global Development

Treasurer

D. Stafford O'Kelly
Abbott Molecular Inc. (Ret.)

Secretary

Amy P. Abernethy, M.D., Ph.D.
Duke University Medical Center

Past President & Chair

J. Brian Munroe
Endo Pharmaceuticals

Past Chair

Wayne A. Rosenkrans, Jr., Ph.D.
MIT (Ret.)

Steven Averbuch, M.D.

Bristol-Myers Squibb

Patrick J. Balthrop

Luminex Corporation

Paul R. Billings, M.D., Ph.D.

Thermo Fisher Scientific

Jeffrey Cossman, M.D.

United States Diagnostic Standard
(USDS)

Neil de Crescenzo

Emdeon Inc.

Donna Cryer, J.D.

Global Liver Institute

Felix W. Frueh, Ph.D.

Opus Three LLC

Tim Garnett, FRCOG, MFFP, FFPM

Eli Lilly and Company

Julie K. Goonewardene

Member, Board of Trustees,
American Medical Association

Michael Kolodziej, M.D.

Aetna

Lawrence J. Lesko, Ph.D., F.C.P.

University of Florida

Aidan Power, M.B.B.Ch., M.Sc.,

M.R.C Psych.

Pfizer Worldwide Research and
Development

Lori M. Reilly, Esq.

PhRMA

Jared N. Schwartz, M.D., Ph.D.

Leica Biosystems

Michael Vasconcelles, M.D.

Millennium: The Takeda
Oncology Company

Jay G. Wohlgemuth, M.D.

Quest Diagnostics